Efficacy of Aleo Vera Use in Prevention and Treatment of Chemotherapy-Induced Oral Mucositis in a Group of Egyptian Children with Acute Leukemia

evaluatation the efficacy of Aleovera in prevention and treatment of chemotherapy-induced oral mucositis in children suffering from acute leukemia in terms of appearance and severity

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Oral Mucositis Mouth Diseases Stomatitis Stomatognathic Diseases

Age range

3 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of dentistry

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients suffering from Acute leukemia( Acute Lymphocytic Leukemia ).
Patients scheduled for chemotherapy treatment.
Patients who range from 3 to 13 years old.
Patients with no history of any chemotherapy or radiotherapy. 5 -Both sexes Exclusion Criteria

1-Patients scheduled for radiotherapy treatment . 2-Existence of any signs or symptoms of oral mucositis. 3-Unwilling to participation in the study 4- Patients with any other systemic diseases or other neoplasms.

Treatment and study plan

Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis

Other

Second arm : aleovera 3 times daily after brushing teeth

Primary outcomes

Prevention of oral mucositis

Time frame: 2 months

Assessment the efficacy of aleo vera gel on prevention of chemotherapy-induced oral mucositis through application the gel 3 times daily then patients were assessed daily in terms of appearance and severity of oral mucositis according WHO grading system.

The World Health Organization (WHO) mucositis scale is used to grade the severity of oral mucositis.

Grade 0: No mucositis Grade 1: Soreness/erythema only. Grade 2: Erythema, and ulcers. Able to tolerate solids. Grade 3: Unable to tolerate solids but able to tolerate liquids. Grade 4: Unable to tolerate solids or liquids. Oral alimentation is not possible.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Jan 3, 2025
Registry last updated: Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed